prof. MUDr. Mgr. Marek Mráz, Ph.D.
Research Group Leader Senior, Marek Mráz Research Group
Office: bldg. E35/216
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 8143 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 267
2021
-
PI3KD inhibitor idelalisib snižuje hladiny CD20 u chronické lymfocytární leukémie inhibicí IL4-STAT6 signální dráhy.
Year: 2021, type: Conference abstract
-
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion
Leukemia Research, year: 2021, volume: 111, edition: December 2021, DOI
-
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
Leukemia, year: 2021, volume: 35, edition: 5, DOI
-
The biology of miRNAs in B cell malignancies and their use as biomarkers.
Year: 2021, type: Conference abstract
-
The role of long non-coding RNAs in the BCR-mediated activation of malignant B cells.
Year: 2021, type: Conference abstract
2020
-
Analysis mutational landscape in systemic anaplastic large cell lymphoma identifies novel prognostic markers
Year: 2020, type: Conference abstract
-
Development of novel patient-derived xenograft model of chronic lymphocytic leukemia.
Year: 2020, type: Conference abstract
-
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
Frontiers in Oncology, year: 2020, volume: 10, edition: OCT, DOI
-
Laboratorní analýza odpovědí na cílenou léčbu u CLL: jen vědecká obsese nebo cesta k průlomové léčbě?
Year: 2020, type:
-
mir-29 influences CD40 signaling in chronic lymphocytic leukemia (CLL)
Year: 2020, type: Conference abstract